Silvana Canevari
Overview
Explore the profile of Silvana Canevari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
3245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenoci D, Resteghini C, Serafini M, Pistore F, Canevari S, Ma B, et al.
Transl Res
. 2024 Dec;
276():21.
PMID: 39689465
No abstract available.
2.
Lenoci D, Moresco E, Cavalieri S, Bergamini C, Torchia E, Botta L, et al.
Front Oncol
. 2024 Oct;
14:1452909.
PMID: 39421447
Oral cavity squamous cell carcinoma (OCSCC) predominantly affects the tongue and the floor of the mouth, primarily in patients over 50 years of age. Incidence and mortality rates vary significantly...
3.
Serafini M, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38290766
Background: Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit...
4.
Cavalieri S, Bruno E, Serafini M, Lenoci D, Canevari S, Lopez-Perez L, et al.
Front Oncol
. 2024 Jan;
13:1321174.
PMID: 38239654
Background: There is a strong need for preventive approaches to reduce the incidence of recurrence, second cancers, and late toxicities in head and neck squamous cell carcinoma (HNSCC) survivors. We...
5.
Lenoci D, Resteghini C, Serafini M, Pistore F, Canevari S, Ma B, et al.
Transl Res
. 2023 Nov;
265:1-16.
PMID: 37949350
Epstein-Barr virus (EBV) related- nasopharyngeal carcinoma (NPC) is a squamous carcinoma of the nasopharyngeal mucosal lining. Endemic areas (EA) are east and Southeast Asia, were NPC was recorded with higher...
6.
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, et al.
Nat Commun
. 2023 Jul;
14(1):4180.
PMID: 37491373
All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report...
7.
Bax H, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, et al.
Br J Cancer
. 2022 Nov;
128(2):342-353.
PMID: 36402875
Background: Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the...
8.
Cavalieri S, Serafini M, Carenzo A, Canevari S, Lenoci D, Pistore F, et al.
Cells
. 2022 Oct;
11(19).
PMID: 36231138
Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims...
9.
Locati L, Serafini M, Carenzo A, Canevari S, Perrone F, Orlandi E, et al.
Front Oncol
. 2022 Jan;
11:799453.
PMID: 35083153
In an immune-competent context nivolumab showed long-term benefit in overall survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, in special cancer population such as these patients with...
10.
Frigerio B, Luison E, Desideri A, Iacovelli F, Camisaschi C, Seregni E, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944686
Prostate cancer (PCa) is the second leading cause of cancer among men, and its diagnosis and adequate staging are fundamental. Among the biomarkers identified in recent years for PCa management,...